/ACET
ACET Stock - Adicet Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.49+5.04%
+$0.02 (+5.04%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6482.9%upside
Target: $32.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACET
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.49 – $0.50
TARGET (TP)$32.50
STOP LOSS$0.45
RISK/REWARD1:732.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.62
52W High$1.11
52W Low$0.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $24.99M | $9.73M | $17.90M |
| Gross Profit | N/A | N/A | $24.99M | $9.73M | $17.90M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-127,615,000 | $-152,038,000 | $-72,551,000 | $-61,433,000 | $-39,191,000 |
| Net Income | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 | $-36,678,000 |
| Net Margin | N/A | N/A | -279.3% | -637.2% | -204.9% |
| EPS | $-1.33 | $-3.31 | $-1.70 | $-2.00 | $-5.01 |
Company Overview
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
25%
Hold / Neutral
3
75%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish3 Neutral/Bearish
Price Targets
$12
Average Target
↑ 2330.6% Upside
Now
$6
Low
$12
Average
$23
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2024 | Guggenheim | Resumed | Buy | $7 |
| September 11th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| June 27th 2023 | Guggenheim | Downgrade | Neutral | - |
| June 27th 2023 | JMP Securities | Downgrade | Market Perform | - |
| June 1st 2023 | JP Morgan | Downgrade | Neutral | $6← $20 |
| September 21st 2022 | JP Morgan | Initiation | Overweight | $23 |
Earnings History & Surprises
ACETBeat Rate
56%
Last 18 quarters
Avg Surprise
+7.4%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.29
Q4 2025
EPS Surprise History
Q1 24
+4.2%
$-0.69vs$-0.72
Q2 24
0.0%
$-0.35vs$-0.35
Q3 24
+5.7%
$-0.33vs$-0.35
Q4 24
+5.6%
$-0.34vs$-0.36
Q1 25
+13.5%
$-0.32vs$-0.37
Q2 25
+8.8%
$-0.31vs$-0.34
Q3 25
-6.3%
$-0.34vs$-0.32
Q4 25
-11.5%
$-0.29vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.34 | $-0.31 | +8.8% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.36 | $-0.34 | +5.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.35 | $-0.33 | +5.7% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.35 | $-0.35 | 0.0% | = MET |
Q1 2024 | Mar 19, 2024 | $-0.72 | $-0.69 | +4.2% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.73 | $-0.71 | +2.7% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.68 | $-0.75 | -10.3% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.74 | $-0.72 | +2.7% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.56 | $-0.72 | -28.6% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.56 | $-0.53 | +5.4% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.45 | $-0.56 | -24.4% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.18 | $0.10 | +155.6% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-0.44 | $-0.47 | -6.8% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.38 | $-0.44 | -15.8% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.51 | $-0.34 | +33.3% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $9
📈 PositiveBenzinga•Nov 7, 2025, 12:38 PM
Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:09 PM
Adicet Bio Doses First Patient In Phase 1 Trial Of ADI-001 For Treatment-Refractory Rheumatoid Arthritis
📈 PositiveBenzinga•Oct 16, 2025, 11:06 AM
Guggenheim Maintains Buy on Adicet Bio, Raises Price Target to $8
📈 PositiveBenzinga•Oct 8, 2025, 12:29 PM
Adicet Bio launches $80M securities offering
➖ NeutralSeeking Alpha•Oct 7, 2025, 11:13 AM
Adicet Bio Priced Registered Direct Offering Of 70M Shares At $1/Share, And Pre-funded Warrants To Purchase 10M Shares At $0.9999 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $80M
➖ NeutralBenzinga•Oct 7, 2025, 11:03 AM
Adicet Bio Shares Initial Safety And Efficacy Data From The First Seven Patients Dosed With ADI-001 In The Ongoing Phase 1 Study In Patients With Autoimmune Diseases
➖ NeutralBenzinga•Oct 7, 2025, 10:51 AM
Guggenheim Reiterates Buy on Adicet Bio, Maintains $7 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 12:45 PM
Frequently Asked Questions about ACET
What is ACET's current stock price?
Adicet Bio, Inc. (ACET) is currently trading at $0.49 per share. The stock has moved +5.04% today.
What is the analyst price target for ACET?
The average analyst price target for ACET is $32.50, based on 1 analyst.
What sector is Adicet Bio, Inc. in?
Adicet Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACET's market cap?
Adicet Bio, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does ACET pay dividends?
No, Adicet Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
Explore stocks similar to ACET for comparison